CC-42344 Phase 1 study with single-ascending dose (SAD) and multiple-ascending dose (MAD) parts.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Part 1 SAD: Number of Participants With Treatment-Emergent Adverse Events (TEAE)
Timeframe: Up to 16 days
Part 1 SAD: Number of Participants With Clinically Significant Laboratory Abnormalities
Timeframe: Up to 16 days
Part 1 SAD: Number of Participants With Clinically Significant Changes From Baseline in Vital Signs
Timeframe: Up to 16 days
Part 1 SAD: Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECGs)
Timeframe: Up to 16 days
Part 2 MAD: Number of Participants With Treatment-Emergent Adverse Events (TEAE)
Timeframe: Up to 21 days
Part 2 MAD: Number of Participants With Clinically Significant Laboratory Abnormalities
Timeframe: Up to 21 days
Part 2 MAD: Number of Participants With Clinically Significant Changes From Baseline in Vital Signs
Timeframe: Up to 21 days
Part 2 MAD: Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECGs)
Timeframe: Up to 14 days